Richard Pittsley, MD
Rheumatology · East Lansing, MINPI 1902821671
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 68.2% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $12,704 and has fallen 88.3% since, to $1,484 in 2025.
Across 581 payments — averaging $37.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$15K
- Johnson & Johnson$2K
- Amgen$2K
- UCB, Inc.$854
- Novartis$728
- Radius Health, Inc.$246
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$11,05051%
- Travel & lodging$9855%
- Food & beverage$9,43043%
- Education$4152%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 176 | $14,916 |
| Johnson & Johnson | 149 | $2,095 |
| Amgen(2 entities) | 87 | $1,630 |
| UCB, Inc. | 36 | $854 |
| Novartis | 40 | $728 |
| Radius Health, Inc. | 9 | $246 |
| E.r. Squibb & Sons, L.L.C. | 13 | $205 |
| Boehringer Ingelheim | 10 | $165 |
| Mallinckrodt Hospital Products Inc. | 8 | $140 |
| Regeneron Healthcare Solutions, Inc. | 12 | $116 |
| Janssen Scientific Affairs, LLC | 2 | $114 |
| Lilly USA, LLC | 5 | $89 |
| Genentech USA, Inc. | 5 | $87 |
| Organon | 5 | $83 |
| GSK | 6 | $77 |
| Mallinckrodt Enterprises LLC | 4 | $68 |
| Sobi, Inc | 3 | $58 |
| Fresenius Kabi USA, LLC | 2 | $43 |
| Actelion Pharmaceuticals US, Inc. | 2 | $39 |
| AstraZeneca | 2 | $39 |
| Sandoz | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi | 1 | $19 |
| Mylan Institutional Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,879 in reported general payments places this provider in the 80th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 52 | $354,456 |
| RinvoqUpadacitinib | 14 | $131,647 |
| Humira(Cf)Adalimumab | 19 | $128,371 |
| Enbrel SureclickEtanercept | 16 | $117,168 |
| OtezlaApremilast | 15 | $51,922 |
| MounjaroTirzepatide | 17 | $18,895 |
| MethotrexateMethotrexate Sodium | 200 | $11,196 |
| Duloxetine Hcl | 147 | $6,477 |
| Calcitriol | 76 | $5,200 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 139 | $3,221 |
| Leflunomide | 29 | $3,157 |
| Pregabalin | 60 | $2,615 |
| Sulfasalazine | 48 | $2,473 |
| Alendronate Sodium | 153 | $2,376 |
| Gabapentin | 76 | $2,363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $14,916 | $260,01833 claims |
| AmgenOtezla | $1,630 | $51,92215 claims |
| Lilly USA, LLCMounjaro | $89 | $18,89517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 195 rheumatology providers in Michigan.
Other rheumatology in East Lansing
- Amar MajjhooSaint Clair Shores$1.8M
- Andrew SulichSaint Clair Shores$1.7M
- Dinesh KhannaAnn Arbor$1.2M
- Roman CzubatyjRochester Hills$764K
- Delfin SantosRochester$242K
- Allan MortonWarren$229K
- Elena SchiopuAnn Arbor$180K
- Alireza MeysamiNovi$170K
- Fazleomar MahmoodChelsea$167K
- Barakat ThabetGrand Rapids$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.